ProShares Ultra Nasdaq Biotechnology
Most Recent
Major Biotech ETFs Had Lackluster Performance in the Past Month
The SPDR S&P Biotech ETF (XBI) is trading at a PE ratio of 20.4x. It reported a one-year return of ~19.7% and a three-year return of ~10.9%.
Must-Know Developments for Ionis Pharmaceuticals
Ionis entered a collaborative agreement with Suzhou Ribo Life Science for the development and commercialization of RNA-targeted therapeutics in China in April 2017.
What Are Analysts Saying about Horizon Pharma?
According to a Thomson Reuters Eikon consensus of six brokerage firms on December 17, 2016, 83.3% of the firms rated Horizon Pharma (HZNP) a “buy.”
Horizon Pharma’s Steep Fall in December: What Happened?
On December 8, 2016, Horizon Pharma (HZNP) announced that its Phase 3 STEADFAST trial for Actimmune didn’t meet its primary endpoint. Horizon stock fell 22.5% that day.
Buy Allows Horizon to Further Expand into Orphan Drug Space
Through the acquisition of Raptor Pharmaceuticals, Horizon Pharma (HZNP) will gain access to Procysbi and Quinsair and expand in the orphan drug space.
How Will Shire’s LSD Portfolio Perform in 2016?
Shire’s (SHPG) LSD (or lysosomal storage disorders) portfolio consists of Elaprase, Replagal, and Vpriv.
How Does Shire’s Late-Stage Pipeline Look?
SHP643, a phase three candidate, might present significant growth potential for Shire (SHPG) in the hereditary angioedema (or HAE) space.
Could JZP-110 Offset Xyrem’s Probable Sales Decline?
Jazz Pharmaceuticals (JAZZ) acquired the rights to develop, manufacture, and market JZP-110 from Aerial BioPharma in January 2014.
Shire Won Patent Infringement Case for Lialda
In fiscal 2015, Lialda added $684.4 million to Shire’s (SHPG) top line, reflecting an 8% annual increase in sales. This was supported by a 10% rise in prescription volume.
How Has Shire Benefited from NPS Pharmaceuticals Acquisition?
In February 2015, Shire (SHPG) completed its acquisition of NPS Pharmaceuticals for $5.2 billion. Through the merger, Shire gained access to Gattex and Natpara.
How Could Baxalta Acquisition Become a Catalyst for Shire?
Shire’s (SHPG) acquisition of Baxalta could prove to be a catalyst for Shire’s valuation in the near term. The combined entity is expected to record revenues of $20 billion by fiscal 2020.
Must-know: Are market valuations stretched?
The NASDAQ Biotechnology Index (IBB) is up 14% this year—less than a third of its 122 companies earned any money in the last 12 months.
